Searched for: in-biosketch:true
person:rentea01
Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma
Kim, Sara S; Renteria, Anne S; Steinberg, Amir; Banoff, Karen; Isola, Luis
BACKGROUND AIMS/OBJECTIVE:Stem cell collection can be a major component of overall cost of autologous stem cell transplantation (ASCT). Plerixafor is an effective agent for mobilization; however, it is often reserved for salvage therapy because of its high cost. We present data on the pharmacoeconomic impact of the use of plerixafor as an up-front mobilization in patients with multiple myeloma (MM). METHODS:Patients with MM who underwent ASCT between January 2008 and April 2011 at the Mount Sinai Medical Center were reviewed retrospectively. In April 2010, practice changes were instituted for patients with MM to delay initiation of granulocyte-colony-stimulating factor (G-CSF) support from day 0 to day +5 and to add plerixafor to G-CSF as an up-front autologous mobilization. Targets of collection were 5-10 × 10(6) CD34(+) cells/kg. RESULTS:Of 50 adults with MM who underwent ASCT, 25 received plerixafor/filgrastim and 25 received G-CSF alone as an up-front mobilization. Compared with the control, plerixafor mobilization yielded higher CD34(+) cell content (16.1 versus 8.4 × 10(6) CD34(+) cells/kg; P = 0.0007) and required fewer sessions of apheresis (1.9 versus 3.1; P = 0.0001). In the plerixafor group, the mean number of plerixafor doses required per patient was 1.8. Although the overall cost of medications was higher in the plerixafor group, the cost for blood products and overall cost of hospitalization were similar between the two groups. CONCLUSIONS:Up-front use of plerixafor is an effective mobilization strategy in patients with MM and does not have a substantial pharmacoeconomic impact in overall cost of hospitalization combined with the apheresis procedure.
PMID: 24927717
ISSN: 1477-2566
CID: 5761622
Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis [Letter]
Freeman, B; Brauneis, D; Seldin, D C; Quillen, K; Sloan, J M; Renteria, A S; Shelton, A C; Teschner, T; Finn, K T; Sanchorawala, V
PMID: 24955784
ISSN: 1476-5365
CID: 5761632
Locally advanced pancreatic cancer in a socio-economically challenged population
Renteria, Anne S; Holland, Bart K; Huang, Yiwu; Cooper, Jay S; Donahue, Bernadine
ORIGINAL:0017487
ISSN: 1548-5315
CID: 5761862
A Unique Case of Classic Kaposi's sarcoma restricted to the toes [Case Report]
Renteria, Anne S; Marshall, Vickie A; Sun, Yanyu; Chockalingam, Porselvi; Cooper, Jay S; Huang, Yiwu; Whitby, Denise
BACKGROUND:Kaposi's sarcoma associated-herpesvirus causes all forms of Kaposi's sarcoma, and six major subtypes have been described based on the amino acid sequences of the open reading frame K1. MAIN OBSERVATION/METHODS:A 71-year-old man from China, HIV negative, presented with nodules on the dorsal aspect of his toes. Biopsy confirmed the diagnosis of Kaposi's sarcoma and virology studies of his blood and saliva confirmed the presence of Kaposi's sarcoma associated-herpesvirus infection. Viral genotyping was consistent with subtype C3. Intervention has been deferred as our patient has remained clinically asymptomatic and without evident growth of his lesions over a 2-year follow up. CONCLUSIONS:We herein report the first known case of Kaposi's sarcoma restricted to the toes caused by the viral subtype C3 in an HIV-negative patient from Harbin, China.
PMCID:3797018
PMID: 24133565
ISSN: 1898-7249
CID: 5761612
Global burden of disease attributable to diabetes mellitus in Brazil
Oliveira, Andreia Ferreira de; Valente, Joaquim Gonçalves; Leite, Iuri da Costa; Schramm, Joyce Mendes de Andrade; Azevedo, Anne S Renteria de; Gadelha, Angela Maria Jourdan
Type II diabetes mellitus accounts for 90% of all cases of diabetes, and its inclusion in health evaluation has shown that its complications have a considerable impact on the population's quality of life. The current article presents the results of the Global Burden of Disease Study in Brazil for the year 1998, with an emphasis on diabetes mellitus and its complications. The indicator used was disability-adjusted life years (DALY), using a discount rate of 3%. In Brazil, ischemic heart disease, stroke, and diabetes accounted for 14.7% of total lost DALYs. Brazil showed a higher proportion of years lived with disability (YLDs) among total DALYs for diabetes as compared to other countries. Retinopathy and neuropathy were the complications that contributed most to YLDs. According to forecasts, diabetes mellitus will have an increasing impact on years of life lost due to premature death and disability in the world, shifting from the 11th to 7th cause of death by 2030. It is thus urgent to implement effective measures for prevention, early diagnosis, counseling, and adequate follow-up of patients with diabetes mellitus.
PMID: 19503954
ISSN: 1678-4464
CID: 5761602